Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CC 19.79 -0.66(-3.23%)
Will CC be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CC
Huntsman's Q3 Earnings Surpass Estimates, Revenues Miss
Albemarle's Q3 Earnings and Sales Miss on Lower Lithium Pricing
CC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Air Products' Q4 Earnings Top Estimates, Revenues Miss
Cabot's Q4 Earnings and Revenues Miss Estimates, Rise Y/Y
Kronos Worldwide's Earnings Surpass Estimates in Q3, Sales Lag
Other News for CC
The Chemours Co (CC) Shares Down 3.79% on Nov 8
YieldBoost Chemours From 4.9% To 20.5% Using Options
Analysts Offer Insights on Materials Companies: Chemours Company (CC), Sibanye Stillwater (SBSW) and Intrepid Potash (IPI)
Chemours price target lowered to $25 from $30 at Morgan Stanley
Chemours price target lowered by $5 at Morgan Stanley, here's why